People who bought the QVAR asthma inhaler could be eligible for a share of a $35 million settlement, but the window to file a claim closes on July 31. The case centers on allegations that Teva Pharmaceuticals kept inhaler prices artificially high by listing device patents in a federal registry that effectively blocked generic competitors from entering the market. An appellate court ordered those patents delisted, and the Federal Trade Commission called the ruling a win for competition and lower drug costs.
How Teva’s patent listings blocked cheaper inhalers
The core dispute involves the FDA’s Orange Book, a registry of approved drug products and their associated patents. When a brand-name manufacturer lists patents there, generic drugmakers face legal and regulatory hurdles before they can bring competing products to market. The FTC argued that Teva listed patents on its QVAR inhaler that did not meet the statutory requirements under 21 CFR 314.53, the federal regulation governing which patents belong in the registry. By keeping those patents listed, Teva allegedly shielded QVAR from generic competition and maintained higher prices for years.
An appellate court agreed and ordered the patents delisted. In a public statement, the FTC described the ruling on Teva’s inhaler patents as an important step toward promoting competition and lowering drug costs for patients who rely on inhaled medications. The settlement includes both a cash fund for purchasers and a delisting component designed to clear the path for lower-cost alternatives. By removing the disputed patents from the listing, regulators aim to reduce the legal risk for generic applicants and encourage new market entrants.
What the July 31 deadline means for QVAR buyers
For anyone who purchased QVAR out of pocket or paid a copay, the deadline to submit a claim is July 31. The $35 million settlement fund is intended to compensate buyers who paid inflated prices during the period when the disputed patents allegedly kept generics off pharmacy shelves. Claimants may include patients, caregivers, and in some cases third-party payers that covered part of the cost, though the precise categories and dates are defined by the settlement terms.
Filing typically requires proof of purchase or pharmacy records, and the settlement administrator is responsible for reviewing submissions and calculating payments. That process often involves matching prescription dates, quantities, and payment amounts to the covered time period. People without paper receipts may still be able to obtain documentation from their pharmacy or insurer, which usually maintains electronic records for several years.
The practical first step for affected buyers is to locate pharmacy receipts, insurance statements, or prescription records showing QVAR purchases and submit a claim before the end of July. Many settlement websites provide online claim forms, mailing addresses, and frequently asked questions explaining what documentation is acceptable. Waiting until after the deadline will likely forfeit any right to a payout from this particular settlement, even for people who clearly bought the inhaler during the covered period.
Whether delisting will actually lower inhaler prices
Removing Teva’s patents from the Orange Book clears one of the biggest barriers to generic approval, but cheaper inhalers will not appear on pharmacy shelves overnight. Generic drugmakers still need FDA approval for their products, and the agency’s review timelines can stretch for months. Companies must show that their inhalers deliver the same active ingredient, at the same dose, with similar performance characteristics, which can be more complex for inhaled drugs than for tablets or capsules.
The FDA’s searchable database of patent and exclusivity data will be one place to monitor for changes that signal generic applications are progressing. As patents are delisted and exclusivities expire, would-be competitors gain clearer legal footing to pursue approval. However, manufacturers still must decide whether the potential market justifies the cost of development and litigation risk.
The FTC has framed the delisting order as a step toward restoring competition, but several questions remain open. No public data confirms how many QVAR purchasers are eligible for the settlement or what individual payouts might look like once the fund is divided among approved claims. Payouts typically depend on how many people file, the size of their documented purchases, and administrative costs deducted from the fund.
The timeline for any generic QVAR inhaler reaching consumers depends on manufacturer decisions and FDA review capacity, neither of which has been publicly forecast. Even after approval, pharmacies and insurers may take time to update formularies and stocking practices, and doctors may need to adjust prescribing habits. In the near term, the most concrete benefit available to buyers is the cash compensation from the settlement, provided they submit claims on time.
For patients still using QVAR or similar inhalers, the delisting decision may eventually translate into more options and lower prices, but that outcome is not guaranteed. Market dynamics, including the number of generic entrants and insurer coverage policies, will shape how much savings reach consumers. Until those developments play out, eligible purchasers have a narrow window to seek direct reimbursement for past overpayments tied to Teva’s now-delisted patents.
